Igufighter Tablet contains Iguratimod 25 mg, a disease-modifying antirheumatic drug (DMARD) primarily indicated for the treatment of rheumatoid arthritis (RA). Iguratimod exerts its therapeutic effect by inhibiting the production of pro-inflammatory cytokines such as interleukin-1, interleukin-6, and tumor necrosis factor-alpha, thereby reducing synovial inflammation and joint destruction. It also modulates immune responses by suppressing B cell activation and antibody production, contributing to its efficacy in autoimmune conditions. Igufighter is administered orally and is typically prescribed as part of a comprehensive treatment regimen including nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids, depending on disease severity. Clinical studies have demonstrated that Iguratimod improves joint swelling, tenderness, and physical function, while slowing radiographic progression of joint damage. Common adverse effects include gastrointestinal disturbances, elevated liver enzymes, and mild hematological abnormalities; therefore, regular monitoring of liver function tests and blood counts is recommended during therapy. Igufighter should be used with caution in patients with hepatic impairment and is contraindicated in pregnancy and lactation due to potential teratogenic effects. Patient adherence and periodic evaluation by a healthcare professional are essential to optimize therapeutic outcomes and minimize risks associated with long-term treatment.